Optomed Oyj: Optomed and Aireen Announce Strategic Partnership and Achieve Approval for AI-Powered Handheld Diabetic Retinopathy Screening
Optomed Plc Press Release 12 January 2026 at 9.00, Helsinki
Optomed and Aireen Announce Strategic Partnership and Achieve Approval for AI-Powered Handheld Diabetic Retinopathy Screening
Optomed and Aireen a.s., a pioneer in AI-driven medical diagnostics, today announced a strategic partnership to deliver AI-powered handheld imaging solutions. As part of this collaboration, Optomed's flagship handheld fundus camera, Optomed Lumo®, has been approved for integration with Aireen's AI algorithm for diabetic retinopathy screening in the EU market.
This regulatory milestone enables the commercial launch of Optomed Lumo with Aireen AI integration across European markets. Aireen's algorithm is certified as an MDR Class IIb CE-marked medical device, ensuring compliance with the highest European safety and performance standards.
The combined solution brings AI-powered diabetic retinopathy screening directly into primary care, ophthalmology practices, mobile screening programs, and healthcare systems-expanding access to early detection and reducing the burden on specialist care.
Beyond diabetic retinopathy, the partnership lays the groundwork for future AI diagnostic applications on the Optomed Lumo platform, potentially addressing a wider range of retinal and systemic diseases to further enhance the value of handheld imaging technology.
"This partnership represents our commitment to transforming handheld imaging into a scalable AI-powered diagnostic platform," said Juho Himberg, CEO of Optomed Plc. "The Optomed Lumo was engineered as an ideal AI integration platform, and achieving regulatory approval with Aireen AI integrated validates this strategy while opening the door to future AI-enabled solutions."
A recent study published in Diabetes Technol Ther. (2025) confirmed the clinical performance of Aireen's diabetic retinopathy algorithm, which demonstrated 94.8% sensitivity, 91.4% specificity, and 92.7% overall accuracy using Optomed's handheld imaging.
"We are thrilled to partner with Optomed to make AI-powered diabetic retinopathy screening more accessible than ever," said Jiří Kuchyňa, CEO of Aireen a.s. "The recent clinical study confirms that our AI algorithm delivers specialist-level performance when used with a handheld device like the Optomed Lumo. The level of accuracy, combined with the portability and usability of Optomed Lumo, has the potential to transform how and where retinal screening can be delivered, from primary care to mobile screening programs. We see this as an important step toward our shared vision of enabling earlier detection, reducing preventable vision loss, and easing the burden on specialist care."
With diabetes prevalence rising globally, the demand for scalable, cost-efficient, and accessible screening solutions is accelerating. This partnership positions Optomed and Aireen at the forefront of the fast-growing market for AI-driven diagnostic tools, combining cutting-edge imaging technology with advanced AI diagnostics to improve patient outcomes and expand healthcare capacity.
Optomed Plc
Further enquiries
Juho Himberg, CEO, Optomed Plc, juho.himberg@optomed.com
Optomed in Brief
Optomed is a Finnish medical technology company and a leading provider of handheld fundus cameras. Our AI-powered screening solutions aim to transform diagnostic processes of various diseases and empower early detection. Our technology is extensively patented, clinically validated and has approvals in all key markets, including CE, FDA and CFDA. Optomed's products are sold via various sales channels in over 60 countries globally. Optomed - Enabling Screening for All
Aireen in Brief
Aireen a.s. is a Czech medical technology company developing AI-driven diagnostic software that detects early symptoms of systemic diseases through retinal imaging. Its CE-marked Class IIb AI solution enables fully automated detection and grading of diabetic retinopathy from retinal images, supporting large-scale preventive screening in primary care, ophthalmology practices, and mobile programs. Aireen's technology is clinically validated, regulation-compliant, and designed for seamless integration with fundus cameras, PACS, HIS, and other healthcare platforms. Aireen - Scaling care for millions. Instantly.
-------------------------------------------------------------------------------------------------------------------------------
References:
¹ Huhtinen P, Kubin AM, Dvořák K, Sliva M, Bayer J, Hautala N. Real-World Evaluation of Artificial Intelligence-Based Diabetic Retinopathy Screening Using the Optomed Aurora Handheld Fundus Camera. Diabetes Technol Ther. Published online August 18, 2025. doi:10.1177/15209156251369886